Navigation Links
Cancer Drug Appears to Help With Aggressive MS
Date:6/12/2008

Use of cyclophosphamide sees 87% improvement in physical, mental function, study says

THURSDAY, June 12 (HealthDay News) -- High doses of a drug used to fight cancer may reduce disease activity and disability in people with aggressive multiple sclerosis, results of a small trial suggest.

In relapsing-remitting MS, the most common type of the disease, patients experience periods of symptoms followed by stretches of symptom-free remission when they used the immunosuppressant drug cyclophosphamide.

In the two-year open label trial that included nine patients with aggressive relapsing-remitting MS, six men and three women with the average age of 35, received 50 milligrams per kilogram per day of cyclophosphamide intravenously for four consecutive days.

After an average of 23 months follow-up, the patients experienced an average 39.4 percent reduction in disability and an 87 percent improvement on scores of physical and mental function. MRI imaging showed a decrease in the average number of MS-related brain lesions, from 6.5 to 1.2 lesions.

"High-dose cyclophosphamide (sold commercially as Cytoxan or Neosar) induced a functional improvement in most of the patients we studied," wrote lead author Chitra Krishnan of the Bloomberg School of Public Health at Johns Hopkins University in Baltimore, Md. "In many of those patients, the functional improvement was sustained through the length of the study (up to 24 months) despite the absence of any immunomodulatory therapies beyond the initial high-dose cyclophosphamide treatment," she concluded.

The study was published online this week in the journal Archives of Neurology and was expected to be in the August print issue.

Cyclophosphamide has been used in combatting a number of cancers, including lymphomas, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, ovarian carcinoma, retinoblastoma and breast cancer. The drug affects the function of immune cells known as T and B cells.

Multiple sclerosis is an inflammatory disease in which the protective coating covering nerve cells degenerates. Autoimmune dysfunction -- in which the body attacks itself -- is believed to be linked with MS.

"This immunoablative regimen (an immune-related therapy involving the destruction of a cell population) of cyclophosphamide for patients with aggressive MS is worthy of further study and may be an alternative to bone marrow transplantation," the study authors concluded.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.



-- Robert Preidt



SOURCE: JAMA/Archives journals news release, June 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Drug Appears to Help With Aggressive MS
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... HealthCareMandA.com ... —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , Home health and hospice companies are still popular targets ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee replacement ... (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- According to a new market research report "Medical Radiation ... Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), Safety (Apron, Shields, Face ... market is expected to reach USD 1,215.4 Million by 2021 from USD ... 2021. Continue Reading ... ...
(Date:3/29/2017)... 29, 2017  The Pharmaceutical Care Management Association (PCMA) ... report on patient out-of-pocket spending: ... Services (CMS), the average amount spent out-of-pocket for drugs ... spending in 2016, down from 23% in 2006. ... not a coverage problem. Health plans don,t have unlimited ...
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
Breaking Medicine Technology: